- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- CAL101, Placebo
- Drug
- Lead sponsor
- Calluna Pharma AS
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Denver, Colorado • Miami, Florida + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 262
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- LTP001, Placebo, Standard of Care (SoC)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 40 Years to 100 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 2
- States / cities
- Birmingham, Alabama • Kansas City, Kansas
- Conditions
- Pulmonary Arterial Hypertension, Idiopathic Pulmonary Fibrosis
- Interventions
- bosentan
- Drug
- Lead sponsor
- Rajan Saggar
- Other
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 2
- States / cities
- Los Angeles, California
- Conditions
- Idiopathic Pulmonary Fibrosis (IPF)
- Interventions
- Dasatinib + Quercetin, Placebo
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 2
- States / cities
- Winston-Salem, North Carolina • San Antonio, Texas
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- BMS-986020, Placebo matching with BMS-986020
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 40 Years to 90 Years
- Enrollment
- 325 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 48
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 42 more
- Conditions
- Pulmonary Fibrosis
- Interventions
- A wearable cough monitoring device, the Strados Labs RESPᵀᴹ sensor, with an accompanying mobile application (App) for data collection
- Device
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 4
- States / cities
- Lakewood, Colorado • Reno, Nevada • Winston-Salem, North Carolina + 1 more
- Conditions
- Idiopathic Interstitial Pneumonias / Hypertension,Pulmonary
- Interventions
- Riociguat (Adempas, BAY63-2521), Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 17
- States / cities
- Los Angeles, California • San Francisco, California • Aurora, Colorado + 14 more
- Conditions
- Interstitial Lung Disease, Idiopathic Interstitial Pneumonias, Drug-Induced Pneumonitis, Hypersensitivity Pneumonitis, Radiation Pneumonitis, Pneumoconiosis, Pulmonary Fibrosis
- Interventions
- 68Ga-FAPi-46, Computed Tomography, Positron Emission Tomography, High Resolution Computed Tomography
- Drug · Procedure
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Idiopathic Pulmonary Fibrosis (IPF)
- Interventions
- INS018_055, Placebo
- Drug
- Lead sponsor
- InSilico Medicine Hong Kong Limited
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 8 more
- Conditions
- Idiopathic Pulmonary Fibrosis (IPF)
- Interventions
- Blood draw, Questionnaire
- Other
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- VAY736, Placebo, Standard of Care (SoC)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Aurora, Colorado • Miami, Florida + 4 more
- Conditions
- Idiopathic Pulmonary Fibrosis, Pulmonary Hypertension
- Interventions
- Treprostinil sodium for inhalation
- Drug
- Lead sponsor
- Lung Biotechnology PBC
- Industry
- Eligibility
- 35 Years to 80 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 6
- States / cities
- La Jolla, California • Sacramento, California • Ann Arbor, Michigan + 3 more
- Conditions
- Pulmonary Fibrosis, Interstitial Lung Disease, Lung Fibrosis, Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
- Interventions
- Not listed
- Lead sponsor
- Pulmonary Fibrosis Foundation
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Multi-Disciplinary Patient Centered Rehab and Education
- Other
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Idiopathic Pulmonary Fibrosis, Diffuse Parenchymal Lung Disease, Interstitial Lung Disease
- Interventions
- sirolimus, Placebo
- Drug · Other
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 21 Years to 85 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Pulmonary Fibrosis of Any Cause, Primary Supporters/Caretakers of Patients With Pulmonary Fibrosis
- Interventions
- Not listed
- Lead sponsor
- National Jewish Health
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2019
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- SUPPORT, Currently Available Printed Material
- Other
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 45 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Not listed
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Pulmonary Fibrosis, Rheumatoid Arthritis
- Interventions
- Not listed
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1999 – 2007
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Nintedanib, Pulmonary rehabilitation program
- Drug · Other
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Loma Linda, California • Danbury, Connecticut + 16 more
- Conditions
- Lung Disease, Interstitial, Idiopathic Pulmonary Fibrosis
- Interventions
- Not listed
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Hyperpolarized Xe129
- Drug
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Familial Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis, Familial Interstitial Pneumonia
- Interventions
- Not listed
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 750 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2030
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Therapeutic Plasma Exchange, Rituximab, Intravenous immunoglobulin, Treatment as Usual
- Other · Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Chicago, Illinois • Kansas City, Kansas + 4 more